STA to distribute Alimera’s ILUVIEN in Australia and New Zealand

ILUVIEN is Alimera’s sustained release intravitreal injection for the treatment of diabetic macular edema.

As part of the deal, STA will also be responsible for managing all regulatory and commercial activities for ILUVIEN in those countries.

The deal will include a milestone payment to Alimera for achievement of a public reimbursement listing and a royalty payment based on net sales that will increase as a specific sales target is met.

Alimera president and chief executive officer Dan Myers said the company is happy to have entered into this deal with STA for commercialization of ILUVIEN in Australia and New Zealand.

"STA is the only private pharmaceutical company in Australia dedicated to specialty pharma products," Myers said.

"Not only do they have a proven track record of successful product launches, but they also consistently top the IMS physician surveys for having the most highly qualified and experienced sales force."

ILUVIEN is indicated in Europe for the treatment of vision impairment associated with chronic DME considered insufficiently responsive to available therapies.

Each ILUVIEN implant provides a therapeutic effect of about 36 months by delivering sustained sub-microgram levels of fluocinolone acetonide.

It is injected in the back of the patient’s eye to a position that takes advantage of the eye’s natural fluid dynamics.